Wire
Tilray Brands Says Cannabis Rescheduling Furthers Research, Access; Shares Rise Pre-Bell
Tilray Brands (TLRY) said Thursday that the Trump administration's move to reschedule cannabis from Schedule I to Schedule III under the Controlled Substances Act furthers medical cannabis clinical research, patient access, and industry standardization.The rescheduling represents an inflection point for US drug policy, and Tilray will participate in the emerging regulated medical cannabis market in the country, the company said.Shares of Tilray Brands were up 14% in Thursday premarket trading.Other cannabis stocks like Canopy Growth (CGC), Cronos (CRON), High Tide (HITI), SNDL (SNDL), and Aurora Cannabis (ACB) were also higher following the news of cannabis rescheduling.
$ACB$CGC$CRON$HITI$SNDL$TLRY